Incisionless Antiobesity Device Company, EndoSphere, Makes Early $3.1 Million Close on $5 Million Round

A company developing an incisionless, implantable antiobesity medical device has made an early close of $3.1 million on a series B round of investment that’s expected to reach $5 million. Columbus, Ohio-based EndoSphere will use the series B to commercially launch its Satisphere innovative medical device, which received the CE Mark recently. Additionally, EndoSphere plans to conduct post-clinical market followup studies of the device. The funding was raised from 31 investors, with the first sale occurring on April 12, according to a regulatory document.